Abstract:Abstract Introduction : Assessment of rivaroxaban concentrations is warranted in advanced age patients treated with rivaroxaban, which may instruct individual dose to reduce bleeding risk. Anti-Xa chromogenic assay has been demonstrated good correlation between rivaroxaban plasma concentration and anti-factor Xa activity (AXA) within the clinical therapeutic dose range. We aimed to assess the variability of AXA and explore clinical characteristics associated with AXA in patients over 80 years treated with rivaroxaban in daily practice. Method : This study subjects were patients over 80 years treated with rivaroxaban hospitalized in the Department of Gerontology of Peking University First Hospital from 2016 to 2021. The medical data were extracted from electronic records: baseline characteristics, and AXA including trough and peak at day 3 and day 30 after rivaroxaban therapy. Inter- individual variability was calculated by mean ± SD, max-min and coefficient of variation (CV), which was calculated by(SD/mean) x 100. Intra- individual variability was assessed by paired-samples T test. Spearman and Pearson correlation analysis were used to evaluate the correlation between AXA and PT, APTT, INR, and clinical characteristics. Result : A total of 145 Chinese patients over 80 years old taking rivaroxaban were included in this study, with an average age of 85.9 ± 4.2 years old, among which 101 were males (69.7%). There were 57 patients (39.3%) in rivaroxaban 5mg BID group and 88 patients (60.7%) in 2.5mg BID group. In terms of interindividual variation, the CV of AXA trough value in patients using rivaroxaban ranged from 58–77%, and the CV of AXA peak ranged from 48–53%. For intra-individual variability, there was no significant difference of the AXA between day 3 and day 30. Body weight was positively correlated with AXA peak of rivaroxaban 5mg BID group (r = 0.331, p = 0.019). ADL score was positively correlated with AXA trough (r = 0.264, p = 0.020) and AXA peak (r = 0.290, p = 0.010) in rivaroxaban 2.5 mg BID. In the rivaroxaban 2.5mg BID group, creatinine clearance was negatively correlated with AXA trough value (r = -0.400, p = 0.001), and also between AXA peak both in rivaroxaban 2.5 mg BID (r = -0.249, p = 0.029) and rivaroxaban 5 mg BID (r = -0.330, p = 0.018). There was a positive correlation present between PT peak and AXA peak, including rivaroxaban 5 mg BID (r = 0.308, p = 0.033) and rivaroxaban 2.5 mg BID (r = 0.430, p = 0.000), and between PT trough and AXA trough in rivaroxaban 5 mg BID (r = 0.406, p = 0.002). The correlation between APTT and AXA is not significant, except APTT peak and AXA peak in rivaroxaban 2.5 mg BID (r = 0.340, p = 0.000). Conclusion : In this study, in Chinese patients treated with rivaroxaban for more than 80 years, there was significant inter-individual variation in AXA, but not significant intra-individual variation. It is recommended to measure AXA trough and peak into the effective treatment range at the initiation of rivaroxaban treatment in patients over 80 years. Creatinine clearance was inversely correlated with AXA, suggesting an increased risk of bleeding with reduced renal function. There was a significant correlation present between PT and AXA, while the correlation between APTT and AXA was poor.

Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors

Direct Factor Xa Inhibitors (rivaroxaban and Apixaban) Versus Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: A Meta-Analysis of 6 Randomized Clinical Trials

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases

Factor Xa inhibitors, Era to replace traditional anticoagulants

Variability and Clinical Characteristics of Anti-factor Xa Activity Treated with Rivaroxaban in Chinese Patients Aged ≥ 80 years: A Single-center Study

Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak–Trough Levels in an Asian Population: A Multicenter Study

Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays

Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding

Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia

Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits

Antidote Reverses Anticoagulant Effects of Factor Xa Inhibitors in Minutes, Studies Show.

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database

Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations

Comparative Investigation of Thromboelastometry and Thrombin Generation for Patients Receiving Direct Oral Anticoagulants or Vitamin K Antagonists